The bispecific antibody produced using thismethod displayed high potency in the picomolar range against PSMA-expressingprostate cancer cell lines and selectively bound the respective antigensof the constituent Fab fragments (PSMA and CD3), indicating that theconditions used in SPAAC conjugation were sufficiently mild to conservethe biological activity of the parent domains. The gene discussed is FOLH1; the disease is cancer.